Skip to content

Gross Profit at other companies

Rogers Corporation logo
Rogers CorporationROG
$64.6M+13.3%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$19.43M+154%
Kiniksa Pharmaceuticals International, plc logo
Kiniksa Pharmaceuticals International, plcKNSA
$193.47M+61.3%
LQD
Liquidia CorporationLQDA
$1.6M+6.5%
ALN
Alnylam PharmaceuticalsALNY
$959.66M+83.1%
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$77.7M+24.4%
Operating income$41.4M+89.6%
Net income$34.4M+47.2%
EPS (diluted)$0.25+56.3%

Balance sheet

See full
Cash & equivalents$41.0M-38.3%
Total debt$85.2M-7.9%
Total equity$567.6M+62.1%
Total assets$724.0M+43.4%

Cash flow

See full
Operating cash flow$32.6M+2,405%

Valuation

See full
Market cap$2.3B+78.5%
Enterprise value$2.34B+78.3%
P/E7.7×-24.6×
P/S7.7×+2.5×

Profitability

See full
Gross margin89.7%+1.5pp
Operating margin41.7%+29.4pp
Net margin100%+83.9pp

Returns & leverage

See full
Return on equity65%+53.8pp
Debt / equity0.2×-0.1×
Current ratio5.5×-0.4×

Where this comes from

Calculated from Aurinia Pharmaceuticals’s reported figures.

The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's gross profit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aurinia Pharmaceuticals's gross profit?
Aurinia Pharmaceuticals (AUPH) reported gross profit of $71.2M in Q1 2026.
How has Aurinia Pharmaceuticals's gross profit changed year-over-year?
Aurinia Pharmaceuticals's gross profit increased by 32.1% year-over-year, from $53.89M to $71.2M.
What is the long-term trend for Aurinia Pharmaceuticals's gross profit?
Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's gross profit has grown at a 54.0% compound annual growth rate (CAGR), from $44.51M to $250.39M.
What does gross profit mean?
Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.